原发性气管鳞状细胞癌的流行病学与治疗趋势
基于美国国家癌症数据库2004至2012年532例成人原发性气管鳞状细胞癌患者,分析人口学、临床因素及5年总生存。总生存率为25%;多变量分析显示 curative surgery(CS)、CS联合辅助治疗、放化疗及放疗均与死亡风险降低相关。作者认为应结合患者治疗目标、合并症和年龄制定治疗建议。
要点
- 532例患者总生存率为25%,多数为男性、白人,发病高峰在六七十岁。
- 26%接受放化疗(CRT),20%接受局限手术联合辅助治疗(LS+AT)或治愈性手术联合辅助治疗(CS+AT),20%仅接受LS或CS,17%仅接受放疗(RT)。
- 多变量分析中CS、CS+AT、CRT、RT均与死亡风险降低相关(HR分别为0.42、0.44、0.48、0.66)。
核心结论
- 气管鳞状细胞癌越来越多地采用手术和全身治疗联合放疗,生存结局有所改善。
- CS、CS+AT、CRT或RT为不同病变范围的患者提供了生存优势,改善程度因病变范围而异。
- 作者认为前瞻性试验有助于区分不同治疗方式的生存优势,决定治疗建议时应考虑患者治疗目标、合并症和年龄。
研究设计与样本
- 研究为基于美国国家癌症数据库的流行病学与治疗趋势分析,纳入2004年至2012年532例成人原发性气管鳞状细胞癌患者。
- 分析人口学、临床因素及5年总生存,分期分为局限期、区域扩展和远处播散。
- 治疗方式分为无治疗(NT)、局限手术(LS)、治愈性手术(CS)、LS联合任何辅助治疗(LS+AT)、CS联合辅助治疗(CS+AT)、放疗(RT)和放化疗(CRT)。
主要发现
- 总生存率为25%。
- 多数病例为男性、白人,发病在六七十岁。
- 26%的病例接受CRT,20%接受LS+AT或CS+AT,20%仅接受LS或CS,17%仅接受RT。
- 多变量分析中,与NT相比,CS(HR 0.42,95%CI:0.26-0.69)、CS+AT(HR 0.44,95%CI:0.36-0.77)、CRT(HR 0.48,95%CI:0.35-0.67)和RT(HR 0.66,95%CI:0.46-0.94)与死亡可能性降低相关。
- 老年患者和体能状态差的患者即使多变量分析中结局仍更差。
关键数值与推荐
- CS与NT相比死亡风险HR 0.42(95%CI:0.26-0.69)。
- CS+AT与NT相比死亡风险HR 0.44(95%CI:0.36-0.77)。
- CRT与NT相比死亡风险HR 0.48(95%CI:0.35-0.67)。
- RT与NT相比死亡风险HR 0.66(95%CI:0.46-0.94)。
临床怎么用
- 作者认为决定治疗建议时应考虑患者治疗目标、合并症和年龄。
- 作者认为前瞻性试验有助于区分不同治疗方式的生存优势。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Management of tracheal squamous cell carcinoma (TSCC) has been complicated by the lack of prognostic data and staging. We describe the epidemiology of TSCC and current treatment approaches. METHODS: Five hundred thirty-two adult patients with primary TSCC from 2004 to 2012 in the National Cancer Database were identified. Demographic, clinical factors, and 5-year overall survival were analyzed. Staging was classified as localized, regional extension, and distant spread. Treatment modality was defined as "no treatment (NT)," "limited surgery (LS)," "curative surgery (CS)," "LS with any adjuvant therapy (AT) (LS+AT)," "CS with AT (CS+AT)," "radiation therapy (RT)," or "chemoradiation (CRT)." RESULTS: Overall survival was 25%. Majority of cases were males, white, and occurred in sixth/seventh decades. Twenty-six percent of cases received CRT, 20% underwent LS+AT or CS+AT, 20% underwent LS or CS only, and 17% underwent RT alone. On multivariate analysis, CS (HR 0.42, 95% CI: 0.26-0.69), CS+AT (HR 0.44, 95% CI: 0.36-0.77), CRT (HR 0.48, 95% CI: 0.35-0.67), and RT (HR, 0.66 95% CI: 0.46-0.94) were associated with decreased likelihood of death compared to NT. Elderly patients and those with poor performance status had worse outcomes even on multivariate analysis. CONCLUSIONS: TSCC is increasingly treated with surgery and systemic therapy in addition to RT, with improved survival outcomes. CS, CS+AT, CRT, or RT provided improved survival advantage in patients with variable levels of improvement based on the extent of the disease. Prospective trials would help differentiate survival advantages between treatment modalities. Patients' goals of care, comorbidities, and age should be considered when deciding appropriate treatment recommendations. LEVEL OF EVIDENCE: NA Laryngoscope, 130:405-412, 2020.
引用
- Hararah MK, Stokes WA, Oweida A, et al. Epidemiology and treatment trends for primary tracheal squamous cell carcinoma. Laryngoscope. 2019. PMID: 30977524. doi:10.1002/lary.27994
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。